Prognosis

Home / Prognosis

Prognosis

BSI is suggested as a prognostic tool in patients with advanced prostate cancer.

In high-risk and metastatic prostate cancer, BSI is associated with patient survival and correlates with other biomarkers of disease burden while adding independent prognostic information. [1][2][3][4]

The relationship between BSI and predicted median survival time (months) suggests that increased BSI is associated with decreased survival. [1]

Disease progression is more rapid in patients with BSI>1 than in patients with BSI≤1. [2]

BSI correlates with bone alkaline phosphatase (BAP) and prostate specific antigen (PSA), but not with lactate dehydrogenase or hemogloblin (HGB). [3]

The prognostic value of BSI supplements that of other biomarkers of disease burden. [4]

[1]

Sabbatini P, Larson SM, Kremer A, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999; 17: 948-957

[2]

Poulsen M, Rasmussen J, Edenbrandt L, Høilund-Carlsen P, Gerke O, Johansen A, Lund L. Bone Scan Index predicts outcome in patients with metastatic hormone sensitive prostate cancer. BJU Int 2015 Jun 13 doi: 10.1111/bju.13160

[3]

Armstrong AJ, Kaboteh R, Carducci MA, et al. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urol Oncol 2014 Nov;32(8):1308-16. doi: 10.1016/j.urolonc.2014.08.006

[4]

Kaboteh R, Damber JE, Gjertsson P, Höglund P, Lomsky M, Ohlsson M, Edenbrandt L. Bone Scan Index: A prognostic imaging biomarker for high risk prostate cancer patients receiving primary hormonal therapy. EJNMMI Research 2013; 3: 9 doi:10.1186/2191-219X-3-9